Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Jazz Pharmaceuticals Announces Acquisition of Cavion

Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.

Read More »

Neuroscientists at Emory University Terminated Following Scrutiny of Chinese Funding Ties

Emory University in Georgia fired a husband and wife neuroscience research team after they were accused of failing to disclose ties to China that included financial funding.

Read More »

Infuse storytelling with imagination and light up the brain

Our brains are hard-wired to receive information primarily through storytelling. The more imaginative, the better. Imagination is a powerful tool.

Read More »

J&J prices ketamine-like depression treatment at $590-$885 for two doses

Johnson & Johnson said the company’s new nasal spray depression treatment Spravato will be priced at $590 for a 56-milligram dose and $885 for an 84-milligram dosage.

Read More »

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.

Read More »

Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations

Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.

Read More »

7 Biotech Trends to Look Out for in 2019

Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.

Read More »

Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio

Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.

Read More »

Mental health crisis could cost the world $16 trillion by 2030

Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.

Read More »

Impatient patients turn to online ‘buyers club’ for new drugs

Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom